Business Context and Reporting Period
Company: PharmaCyte Biotech, Inc. (PMCB)
Filing Type: Form 8-K (Current Report)
Date of Report: September 2, 2025
Event Date: September 2, 2025 (Agreement); September 4, 2025 (Closing)
Context: The Company entered into a Material Definitive Agreement to acquire equity securities in TNF Pharmaceuticals, Inc. ("TNF") via a private placement.
Key Financial Metrics and Transaction Details
This filing details a specific investment transaction rather than reporting the Company's general operating results. Key financial terms of the transaction include:
- Total Purchase Price: $3,000,000
- Assets Acquired:
- Series H Convertible Preferred Stock of TNF (convertible into 600,000 TNF Common Shares).
- Warrants to purchase up to 600,000 TNF Common Shares.
- Preferred Stock Dividends: 7.0% per annum, compounded monthly (payable in cash). Increases to 15% per annum upon a "Triggering Event."
- Conversion/Exercise Price: $5.00 per share (subject to full ratchet anti-dilution adjustments).
- Warrant Expiration: Five years from the date of Stockholder Approval.
Note: The filing does not provide PharmaCyte Biotech's current revenue, profit, cash flow, or debt levels. It only discloses the capital outlay for this specific transaction.
Material Changes and Transaction Structure
The primary material change is the deployment of $3.0 million in capital to acquire a significant equity position in TNF Pharmaceuticals. Key structural elements include:
- Conversion Rights: Preferred shares convert at the Company's election following Stockholder Approval. Voting rights are on an as-converted basis.
- Triggering Events: Defined events (e.g., failure to file registration statements, failure to pay amounts due) allow the Company to require TNF to redeem shares at a premium and increase dividend accruals to 15%.
- Registration Rights: TNF must file a resale registration statement covering 200% of the conversion and warrant shares within 15 days of closing.
- Covenants: TNF is subject to affirmative and negative covenants regarding indebtedness, restricted payments, asset transfers, and maintaining a cash minimum.
Outlook, Risks, and Contingencies
Management Commentary: The Company issued a press release announcing the transaction on September 2, 2025. The transaction closed on September 4, 2025, subject to customary conditions.
Risks and Contingencies:
- Stockholder Approval: Full conversion and warrant exercise rights are contingent upon TNF stockholders approving the issuance of more than 19.99% of outstanding shares.
- Liquidity of Investment: The securities are not registered under the Securities Act of 1933 until TNF files the required resale registration statement.
- Counterparty Performance: The investment's value and redemption rights depend on TNF's ability to meet covenants, file registration statements, and maintain cash levels.
Investor Verification Checklist
- Verify the status of TNF Pharmaceuticals' stockholder approval for the issuance of the new shares.
- Confirm the filing and effectiveness of the resale registration statement required by the Registration Rights Agreement.
- Review TNF Pharmaceuticals' current financial health and ability to meet the 7% (or 15%) cash dividend obligations.
- Assess the impact of the $3.0 million cash outflow on PharmaCyte Biotech's remaining liquidity (requires review of recent 10-Q or 10-K).
- Monitor for any "Triggering Events" that could alter the dividend rate or redemption terms.